CTLA-4, the first immune checkpoint receptor to be clinically targeted, shares the same ligands, the B7 family (CD80 and CD86), with CD28, which are important to increase T and NK cell tolerance, but which also contributes to an immunosuppressive microenvironment in cancer [62]. Here, CD80 is linked to cancer.